Novonorm (Repaglinide)

Repaglinide belongs to the meglitinide class and works by binding to the sulfonylurea receptor on pancreatic beta‑cell K‑ATP channels. This binding closes the channel, leading to cell depolarization, calcium influx, and rapid release of insulin. The insulin secretion is glucose‑dependent and primarily occurs in response to food intake, thereby reducing post‑prandial blood glucose.

The dose of Novonorm is individualized and set by the prescribing clinician based on factors such as the patient’s blood glucose profile, renal and hepatic function, concomitant medications, and overall treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for repaglinide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit ratio and may consider alternative therapies when safer options are available.

To order Novonorm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Novonorm (repaglinide) is a short‑acting meglitinide, offering rapid insulin release that targets post‑prandial glucose spikes. Compared with longer‑acting sulfonylureas, it has a lower risk of prolonged hypoglycemia and provides more flexible dosing around meals. However, it shares the class‑related risk of hypoglycemia and may require dose adjustments in renal or hepatic impairment.

Novonorm tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the medication out of reach of children and do not use it after the expiration date printed on the packaging.

Novonorm is taken orally as a tablet, usually 15–60 minutes before the start of a meal. The exact timing and number of tablets per day are determined by the prescriber based on the individual’s glycemic targets and meal pattern. It should be swallowed with a glass of water.

The most serious adverse effects of Novonorm include severe hypoglycemia, which can cause confusion, loss of consciousness, or seizures, and rare cases of liver dysfunction or pancreatitis. Patients should be educated to recognize early signs of low blood sugar and seek medical attention promptly if serious symptoms develop.

Novonorm is contraindicated in patients with known hypersensitivity to repaglinide or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment, uncontrolled infection, or in those taking other insulin‑secretagogues that could precipitate dangerous hypoglycemia without close medical supervision.